↓ Skip to main content

ACR Appropriateness Criteria® Resectable Rectal Cancer

Overview of attention for article published in Radiation Oncology, September 2012
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ACR Appropriateness Criteria® Resectable Rectal Cancer
Published in
Radiation Oncology, September 2012
DOI 10.1186/1748-717x-7-161
Pubmed ID
Authors

William E Jones, Charles R Thomas, Joseph M Herman, May Abdel-Wahab, Nilofer Azad, William Blackstock, Prajnan Das, Karyn A Goodman, Theodore S Hong, Salma K Jabbour, Andre A Konski, Albert C Koong, Miguel Rodriguez-Bigas, William Small, Jennifer Zook, W Warren Suh

Abstract

The management of resectable rectal cancer continues to be guided by clinical trials and advances in technique. Although surgical advances including total mesorectal excision continue to decrease rates of local recurrence, the management of locally advanced disease (T3-T4 or N+) benefits from a multimodality approach including neoadjuvant concomitant chemotherapy and radiation. Circumferential resection margin, which can be determined preoperatively via MRI, is prognostic. Toxicity associated with radiation therapy is decreased by placing the patient in the prone position on a belly board, however for patients who cannot tolerate prone positioning, IMRT decreases the volume of normal tissue irradiated. The use of IMRT requires knowledge of the patterns of spreads and anatomy. Clinical trials demonstrate high variability in target delineation without specific guidance demonstrating the need for peer review and the use of a consensus atlas. Concomitant with radiation, fluorouracil based chemotherapy remains the standard, and although toxicity is decreased with continuous infusion fluorouracil, oral capecitabine is non-inferior to the continuous infusion regimen. Additional chemotherapeutic agents, including oxaliplatin, continue to be investigated, however currently should only be utilized on clinical trials as increased toxicity and no definitive benefit has been demonstrated in clinical trials. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 2%
France 1 2%
Italy 1 2%
Unknown 46 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 20%
Student > Master 7 14%
Researcher 5 10%
Professor 4 8%
Student > Doctoral Student 3 6%
Other 11 22%
Unknown 9 18%
Readers by discipline Count As %
Medicine and Dentistry 30 61%
Agricultural and Biological Sciences 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Mathematics 1 2%
Nursing and Health Professions 1 2%
Other 2 4%
Unknown 12 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2012.
All research outputs
#17,666,399
of 22,679,690 outputs
Outputs from Radiation Oncology
#1,271
of 2,045 outputs
Outputs of similar age
#125,150
of 171,470 outputs
Outputs of similar age from Radiation Oncology
#15
of 28 outputs
Altmetric has tracked 22,679,690 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,045 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 171,470 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.